Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Announces $189 Million Agreement for TKI from Hangzhou Company

publication date: Jun 1, 2021

Suzhou Innovent Biologics acquired China rights to co-develop and commercialize taletrectinib, an AnHeart oncology treatment, in a $189 million pact. Taletrectinib as a next-gen TKI that targets ROS1 and NTRK. AnHeart, a Hangzhou company, is already conducting two Phase II trials of  taletrectinib in China, one in NSCLC and the other in solid tumors, plus a global Phase II trial in NSCLC. Patients with ROS1 and NTRK positive NSCLC acquire resistance to existing treatments. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital